The DOI matches its Crossref record; the references it cites are not checked yet.
Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors
Abstract
p300 and CREB-binding protein (CBP) are ubiquitously expressed pleiotropic lysine acetyltransferases and play a key role as transcriptional co-activators that are essential for a multitude of cellular processes. Despite great importance, there is a lack of highly selective, potent, druglike p300/CBP inhibitors. Through the artificial-intelligence-assisted drug discovery pipeline and further optimization, we reported the discovery of novel, highly selective, potent small-molecule inhibitors of p300/CBP histone acetyltransferases (HAT) with desired druglike properties, exemplified by B026 . Our data demonstrated that B026, with half maximal inhibitory concentration (IC 50 ) values of 1.8 nM to p300 and 9.5 nM to CBP enzyme inhibitory activity, is the most potent, selective p300/CBP HAT inhibitor. Moreover, B026 achieves significant and dose-dependent tumor growth inhibition in an animal model of human cancer, suggesting that B026 is a highly promising p300/CBP HAT inhibitor and warrants extensive preclinical investigation as a potential clinical development candidate.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
The citation lists are queued
They are fetched later and appear here then.
References 50 · Cited by 132
Metadata
- Authors
- Yang, Y., Zhang, R., Li, Z., Mei, L., Wan, S., Ding, H., Chen, Z., Xing, J., Feng, H., Han, J., Jiang, H., Zheng, M., Luo, C., & Zhou, B.
- Affiliations
- Chinese Academy of Sciences (CN)
- Dezhou University (CN)
- Corresponding author
- Zheng, Mingyue
- Luo, Cheng
- Zhou, Bing
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-01-07
- Volume
- 63
- Issue
- 3
- Pages
- 1337-1360
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3000630658
- Cited by
- 132
- References
- 50
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 20 · 2023: 24 · 2022: 17 · 2021: 30 · 2020: 10
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology of the People's Republic of China (2017YFB0202604, 2018YFA0508200, 2018ZX09711002-004-012, 2018ZX09711002-004-013, 2018ZX09711002-006-001, 2018ZX09711002-008-005)
- K. C. Wong Education Foundation
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2017333)
- Science and Technology Commission of Shanghai Municipality (17QA1405000, 18431907100, 19XD1404700)
- National Natural Science Foundation of China (21820102008, 81625022, 81773568, 81821005, 81973166, 91753207, 91853205)
- Chinese Academy of Sciences (XDA12020361)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- P300, CREB-binding protein, histone acetyltransferase inhibitors, small molecule inhibitors, enzyme selectivity, oral bioavailability, tumor growth inhibition, cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Enzyme Inhibitors, Female, Humans, Male, Mice, Inbred BALB C, Microsomes, Liver, Neoplasms, Spiro Compounds, Structure-Activity Relationship, Molecular Structure, Neural Networks, Computer, Rats, Sprague-Dawley, Cell Line, Tumor, Cell Proliferation, E1A-Associated p300 Protein, CREB-Binding Protein, Drug Discovery, Molecular Docking Simulation, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors. https://app.cochat.ai/papers/10.1021/acs.jmedchem.9b01721
- The paper
- Yang, Y., Zhang, R., Li, Z., Mei, L., Wan, S., Ding, H., Chen, Z., Xing, J., Feng, H., Han, J., Jiang, H., Zheng, M., Luo, C., & Zhou, B. (2020). Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.9b01721
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.